Recently published scientific studies include research into whether Covid-19 immunity might not be possible.

The U.S. Food and Drug Administration approved Merck’s anti-PD-1 therapy Keytruda as monotherapy for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.

AstraZeneca and Daiichi Sankyo’s Enhertu helped patients with three different types of cancer live longer in trials, pointing to potential broader use of the breast cancer treatment.

Merck’s checkpoint inhibitor Keytruda (pembrolizumab) hit one of the coprimary endpoints early in the Phase III KEYNOTE-177 clinical trial for a highly mutating form of colorectal cancer.

Business updates for various pharma and life science companies around the globe.

Cancer deaths in the United States fell 2.2% from 2016 to 2017 – the largest single-year drop ever recorded – fueled in large part by progress against lung cancer, the leading cause of cancer death, the American Cancer Society (ACS) reported.

Arcus Biosciences and Roche company Genentech are partnering on two clinical trials for colorectal and pancreatic cancer.

An experimental Amgen Inc. drug that targets a specific genetic mutation reduced tumor size in around half of advanced lung cancer patients given the highest dose in a small, early-stage trial.

Freenome snagged $160 million in Series B financing to support the development of the company’s early cancer detection blood test.

Bayer, Bristol-Myers Squibb and Ono Pharmaceutical teamed up to study the most common type of metastatic colorectal cancer.